GENE ONLINE|News &
Opinion
Blog

2021-06-24| ChinaR&D

China’s Legend Biotech to Build a CAR-T Therapy Production Site in Belgium

by Tyler Chen
Share To

Fresh off completing a rolling submission for ciltacabtagene autoleucel (cilta-cel), a CAR-T therapy co-developed with Janssen, China’s Legend Biotech, has announced plans to establish a manufacturing facility in Belgium to boost the production of cilta-cel once it’s FDA approved.

 

Third Plant for Legend Biotech, a First in Europe

The Belgium facility is going to be the first plant in Europe and the third for Legend Biotech on top of the two in Nanjing, China, and New Jersey, US. For now, details of the plant remain unclear, but the site is expected to go into operation by 2023 and focus on manufacturing cell therapy products.

Also, it would put Legend Biotech in a better position to tap the local talent pool and support global supply as soon as cilta-cel gets approved.

 

Collaboration with Janssen

Janssen started working with Legend Biotech on developing CAR-T therapy at the end of 2017. The drug is developed for patients with relapsed/refractory multiple myeloma. It received a Breakthrough Therapy Designation (BTD) in the US in December 2019 and also got priority review in May 2021, meaning the FDA will make the decision by November 29th. What’s more, it’s the first CAR-T therapy accepted for review by the China Food and Drug Administration (CFDA).

 

Approved CAR-T Therapies

If approved, cilta-cel will be the second CAR-T therapy to treat those with relapsed/refractory multiple myeloma as BMS and bluebird bio won the race in March with Abecma, entering the market as the fifth CAR-T therapy and the first for the indication.

Currently, the US FDA has approved five CAR-T therapies, including Abecma and Breyanzi by BMS, Tecartus and Yescarta by Gilead, and Kymriah by Novartis.

Related Article: From Great Challenges to Great Opportunities: An Outlook on US-China Biotech Relationships

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Advancing the Frontiers of Cell and Gene Therapy – An Interview with Dr. Shin Kawamata
2023-11-21
GeneOnline’s Weekly News Highlights: Nov 13-Nov 17
2023-11-20
Pioneering Partnership: Africa CDC and China CDC Elevate Public Health Initiatives
2023-11-20
LATEST
BIODND – An AI-Powered Database That Breaks New Ground in Life Science Business Development
2023-11-29
GeneOnline’s Weekly News Highlights: Nov 20-Nov 24
2023-11-27
SK Bioscience and Hilleman Laboratories Join Forces for Ebola Vaccine Development
2023-11-23
BeiGene to Expand Oncology Pipeline Through ENSEM Therapeutics Partnership
2023-11-23
Advancing the Frontiers of Cell and Gene Therapy – An Interview with Dr. Shin Kawamata
2023-11-21
Astellas and Pfizer’s Drug Receives FDA Approval as Treatment for High-Risk Prostate Cancer Recurrence
2023-11-21
GeneOnline’s Weekly News Highlights: Nov 13-Nov 17
2023-11-20
EVENT
2023-11-30
2023 Healthcare+ EXPO・Taiwan
Taipei , Taiwan
Scroll to Top